Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC (Q83224779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Yulia Volchek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Elizabeth Naparstek

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Israel Gavish

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Itai Levi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jacob M Rowe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Avichai Shimoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Arnon Nagler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

12 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

200-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

20 January 2020

cites work

1 reference

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

7 January 2021

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

7 January 2021

Drug metabolism and variability among patients in drug response

1 reference

7 January 2021

Clinical pharmacokinetics of imatinib

1 reference

7 January 2021

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

7 January 2021

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

1 reference

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

7 January 2021

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

1 reference

7 January 2021

Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome

1 reference

7 January 2021

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

7 January 2021

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

1 reference

7 January 2021

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

7 January 2021

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22241698%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference